IMB Dx, Inc. (KOSDAQ:461030)
South Korea · Delayed Price · Currency is KRW 2,685.00
+90.00 (3.47%)
Sep 22, 2026, 3:30 PM KST
IMB Dx Revenue
IMB Dx had revenue of 1.51B KRW in the quarter ending June 30, 2026, a decrease of -0.03%. This brings the company's revenue in the last twelve months to 5.60B, up 46.12% year-over-year. In the year 2025, IMB Dx had annual revenue of 5.33B with 56.40% growth.
Revenue (ttm)
5.60B
Revenue Growth
+46.12%
P/S Ratio
6.50
Revenue / Employee
n/a
Employees
n/a
Market Cap
36.38B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.33B | 1.92B | 56.40% |
| Dec 31, 2024 | 3.41B | -619.97M | -15.40% |
| Dec 31, 2023 | 4.03B | 1.40B | 53.42% |
| Dec 31, 2022 | 2.62B | 1.39B | 113.34% |
| Dec 31, 2021 | 1.23B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ORIENT BIO | 59.09B |
| Amicogen | 46.69B |
| Prestige BioPharma | 16.21B |
| GeneOne Life Science | 12.37B |
| Genexine | 5.81B |
| iNtRON Biotechnology | 5.74B |
| MedPacto | 4.99B |
| Xcell Therapeutics | 4.36B |